RefleXion Highlights New Cancer Treatment Research at ASTRO 2021

“Particularly gratifying among our multiple abstracts are oral presentations demonstrating physical validation of biological guidance for delivering radiotherapy to an FDG-avid target and exploring whether novel prostate surface membrane antigen radiotracers hold promise for one day enabling BgRT in prostate cancer,” said Shervin ‘Sean’ Shirvani, M.D., M.P.H., chief medical officer at RefleXion. “Also, our earliest clinical adopters are presenting work detailing commissioning of the very first commercial X1 machine, which has delivered hundreds of fractions of conventional radiotherapy, a critical step toward bringing BgRT to the clinic.”

The following presentations taking place during ASTRO 2021 evaluate RefleXion’s X1 technology:

Sunday, Oct 24: Radiation and Cancer Physics

• 1:55 PM 1002 “Feasibility of using FDG in the Stereotactic Ablative Setting for Tracked Dose Delivery with BgRT: Results from a Prospective Study of Serial Inter-Fraction PET/CTs.” (Oral Abstract, Room 178 a/b)
• 4:45 PM 2248 Poster Q&A 02 – Session 02 – “Dosimetric comparison of single-isocenter and multiple-isocenter techniques for two-lesion lung SBRT using the RefleXion high-speed ring-gantry system.” (Room W375)

Monday, Oct 25, 11:20 AM: Radiation and Cancer Physics

• 40 “Physical validation of biology-guided radiotherapy for delivering a tracked dose distribution to a moving PET-avid target.” (Oral Abstract, Room 184 a/b/c/d)

Tuesday, Oct 26:

• 1:30 PM 98 Radiation and Cancer Physics “Evaluation of PSMA-PET biology-guided radiotherapy sequential boost to the dominant intraprostatic lesion in low-volume advanced prostate cancer.” (Oral Abstract, Room W185 a/b/c/d)
• 3:30 PM Poster Q&A 08 – Session 08 – Lung Cancer/Thoracic Malignancies and Palliative Care. (Outside Room 375)
  • 2883 “Disease Burden on FDG-PET Predicts Outcomes for Advanced Non-Small Cell Cancer Patients Treated with First-Line Immunotherapy.”
  • 2884 “Characterization of the Entire Metastatic Spectrum for Non-Small Cell Lung Cancer in the Immunotherapy Era.”

Wednesday, Oct. 27, 10:30 AM: Poster Q&A 09 – Session 09 – Physics Treatment Techniques and Patient Safety (Outside Room 375)

• 3067 “First Beam Commissioning Report of a Novel Medical Linear Accelerator Designed for Biologically Guided Radiotherapy.”
• 3069 “Physical Confirmation of Biology-guided Radiotherapy Directed at Static Targets with Varying Shapes and Background Contrast Environments.”
• 3074 “Comparison of a First-in-class LINAC-integrated PET System and a Diagnostic PET/CT Scanner.”
• 3075 “Initial Evaluation of Biology-guided Radiotherapy (BgRT) Plans Generated Using PET Acquired on the First Installation of Reflexion X1 System.”
• 3115 “The kVCT System Commissioning of a Novel Medical Linear Accelerator Designed for Biology-guided Radiotherapy.”
• 3138 “Utilizing Biology-guided Radiotherapy for Coronary Artery Avoidance During Free-breathing External Beam Radiation Delivery.”

About RefleXion Medical

RefleXion is a privately-held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.

*The RefleXion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to investigational use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005005/en/